Mesenchymal stem cells (MSCs) and morphogenetic protein (rhBMP-2) associated to chemotherapy: a new perspective for a canine osteosarcoma therapy.

• Grant number: 12/21191-6
• Support Opportunities: Regular Research Grants
• Start date: April 01, 2013
• End date: March 31, 2015
• Field of knowledge: Agronomical Sciences - Veterinary Medicine - Animal Reproduction
• Principal Investigator: Rose Eli Grassi Rici
• Grantee: Rose Eli Grassi Rici
• Host Institution: Faculdade de Medicina Veterinária e Zootecnia (FMVZ). Universidade de São Paulo (USP). São Paulo , SP, Brazil
• City of the host institution: São Paulo
• Associated researchers: Durvanei Augusto Maria

Abstract

Osteosarcomas, classified as mesenchymal tumors, described as a malignant bone tumor accounting for 80% of tumors, very common in dogs, cats and humans. Our results "in vitro" suggests that treatment of MSCs with fetal canine bone marrow (MSC) with bone morphogenetic protein (rhBMP-2) was able to induce the osteogenic potential and p53-mediated tumor suppression. "In vivo" we observe that there are no toxicity mechanisms that alter mitochondrial metabolism. Apoptosis found in the different treatments are due to the effects of immunomodulators and rhBMP2 MSC, which represents a potential antitumor and inhibiting the formation of metastases. The proposed project aims to study a new experiment on the effect of tumor suppression using MSC, rhBMP2 association and Carboplatin (chemotherapy) for the treatment of canine osteosarcoma. The cells of canine osteosarcoma (OST) will be deployed in mice BalbC nude / nude after its implementation will be treated with MSC, rhBMP-2 and Carboplatin. The analysis of the samples after treatment will be by flow cytometry using markers that express tumor suppressor, elucidating the mechanism of action of rhBMP-2 MSC and Carboplatin in OST. Cell therapy may be a novel therapeutic strategy and the project is of great relevance, since results obtained "in vivo" and "in vitro" promising. A new treatment strategy in clinical validate therapy for canine osteosarcoma. (AU)

Scientific publications

(The scientific publications listed on this page originate from the Web of Science or SciELO databases. Their authors have cited FAPESP grant or fellowship project numbers awarded to Principal Investigators or Fellowship Recipients, whether or not they are among the authors. This information is collected automatically and retrieved directly from those bibliometric databases.)

RICI, R. E. G.; WILL, S. E. A. L.; LUNA, A. C. L.; MELO, L. F.; SANTOS, A. C.; RODRIGUES, R. F.; LEANDRO, R. M.; MARIA, D. A.. Combination therapy of canine osteosarcoma with canine bone marrow stem cells, bone morphogenetic protein and carboplatin in an in vivo model. VETERINARY AND COMPARATIVE ONCOLOGY, v. 16, n. 4, p. 478-488, DEC 2018. (12/21191-6)